Healthy Participants

141
Pipeline Programs
30
Companies
50
Clinical Trials
10 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
137
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
943%
Monoclonal Antibody
524%
RNA Therapeutic
419%
Peptide
314%
+ 122 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
GRANIXApproved
tbo-filgrastim
Unknown Company
Leukocyte Growth Factor [EPC]injection2012

Competitive Landscape

38 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
2 programs
1
1
Tbo-filgrastimPhase 32 trials
TEV-56286 TestPhase 11 trial
Active Trials
NCT06911567Completed47Est. Jun 2025
NCT03029000Terminated1Est. Oct 2017
NCT02190721Completed50Est. Apr 2017
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN10933 + REGN10987Phase 31 trial
Active Trials
NCT04452318Completed3,303Est. Oct 2021
Pfizer
PfizerNEW YORK, NY
17 programs
16
1
mPnC candidatePhase 21 trial
Bosutinib capsulePhase 13 trials
DanuglipronPhase 11 trial
Oral [14C] PF-06821497Phase 11 trial
Oral [14C]PF-06865571Phase 11 trial
+12 more programs
Active Trials
NCT05032690Completed32Est. Jun 2022
NCT04916769Completed18Est. Jan 2022
NCT04549480Completed66Est. Jan 2021
+16 more trials
Bristol Myers Squibb
17 programs
17
AdmilparantPhase 11 trial
BMS-986036Phase 13 trials
BMS-986165Phase 11 trial
BMS-986165Phase 11 trial
BMS-986205Phase 15 trials
+12 more programs
Active Trials
NCT07225647Completed56Est. Jan 2026
NCT04634149Completed16Est. Jun 2022
NCT04493567Completed102Est. Jun 2021
+27 more trials
E
14 programs
14
AJM347Phase 11 trial
AvatrombopagPhase 11 trial
E2027Phase 11 trial
E2082Phase 11 trial
E2609Phase 11 trial
+9 more programs
Active Trials
NCT03133468Completed200Est. Jul 2018
NCT02809768Completed48Est. Sep 2016
NCT02415790Completed112Est. Jul 2016
+11 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
12 programs
12
AZD0780Phase 15 trials
AZD4144Phase 11 trial
AZD5004Phase 15 trials
AZD5055Phase 14 trials
AZD5462Phase 11 trial
+7 more programs
Active Trials
NCT07216131Completed14Est. Dec 2025
NCT06671405Completed59Est. Feb 2025
NCT06576765Completed16Est. Nov 2024
+28 more trials
UP
12 programs
12
DonzakimigPhase 11 trial
Minzasolmin tablet formulation under fasting conditionPhase 11 trial
PadsevonilPhase 11 trial
Padsevonil type 1 Tablet 200 mgPhase 11 trial
RozanolixizumabPhase 1Monoclonal Antibody1 trial
+7 more programs
Active Trials
NCT06716879Completed32Est. Apr 2025
NCT06533475Completed18Est. Nov 2024
NCT04039919Terminated40Est. May 2020
+9 more trials
Novo Nordisk
8 programs
7
Debio 1453PPhase 11 trial
NNC0113-6856Phase 11 trial
NNC0650-0013 APhase 11 trial
SemaglutidePhase 1Peptide1 trial
SemaglutidePhase 1Peptide1 trial
+3 more programs
Active Trials
NCT02917616Completed30
NCT07035769Recruiting88Est. May 2026
NCT06069895Completed170Est. Apr 2025
+5 more trials
Arcus Biosciences
7 programs
7
CasdatifanPhase 11 trial
EtrumadenantPhase 11 trial
EtrumadenantPhase 1
QuemliclustatPhase 1Small Molecule1 trial
[14C]-etrumadenantPhase 1
+2 more programs
Active Trials
NCT06919991CompletedEst. Oct 2025
NCT05154136CompletedEst. Dec 2021
NCT07364214Active Not RecruitingEst. Apr 2026
+2 more trials
Arvinas
ArvinasCT - New Haven
4 programs
4
MidazolamPhase 1
VepdegestrantPhase 1
VepdegestrantPhase 1
vepdegestrantPhase 1
Moderna
ModernaCAMBRIDGE, MA
3 programs
2
mRNA-0184Phase 1RNA Therapeutic1 trial
mRNA-0184Phase 1RNA Therapeutic1 trial
Wireless wearable digital devicesN/A1 trial
Active Trials
NCT05440318Completed62Est. Feb 2023
NCT06243770Completed44Est. Jun 2025
NCT06655870Active Not Recruiting52Est. Jun 2026
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
AMG 133Phase 15 trials
AMG 510Phase 15 trials
SotorasibPhase 11 trial
Active Trials
NCT07428525Completed36Est. Feb 2026
NCT07429045Completed44Est. Nov 2025
NCT06976372Completed120Est. Dec 2024
+8 more trials
Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
3 programs
3
AficamtenPhase 11 trial
CK-3828136Phase 11 trial
CK-4021586Phase 11 trial
Active Trials
NCT05924815Completed44Est. Nov 2023
NCT05662215Terminated57Est. Aug 2023
NCT05877053Completed102Est. Nov 2024
Genentech
3 programs
3
CobimetinibPhase 1Small Molecule1 trial
DivarasibPhase 11 trial
MidazolamPhase 11 trial
Active Trials
NCT01929876Completed16Est. Oct 2013
NCT06835465Completed18Est. May 2025
NCT03174041Completed63Est. Jun 2017
Ionis Pharmaceuticals
3 programs
3
EplontersenPhase 1RNA Therapeutic1 trial
IONIS FXI-LRxPhase 11 trial
OlezarsenPhase 1RNA Therapeutic1 trial
Active Trials
NCT04302064Completed24Est. Sep 2020
NCT03582462Completed66Est. Apr 2019
NCT05579860Completed104Est. May 2023
Takeda
TakedaTOKYO, Japan
3 programs
3
Esomeprazole CapsulePhase 11 trial
TAK-925Phase 11 trial
TAK-994Phase 13 trials
Active Trials
NCT03083639Completed52Est. May 2017
NCT03748979Completed57Est. Oct 2019
NCT04833049Completed6Est. Jun 2021
+2 more trials
GS
Gilead SciencesFOSTER CITY, CA
3 programs
3
EtrumadenantPhase 11 trial
[14C]-etrumadenantPhase 1
[14C]-etrumadenantPhase 11 trial
Active Trials
NCT05277012Completed24Est. Mar 2022
NCT05411146Completed8Est. Jul 2022
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
3 programs
3
JZP047Phase 11 trial
JZP441Phase 11 trial
JZP441Phase 11 trial
Active Trials
NCT07377539Not Yet Recruiting86Est. Jul 2026
NCT05651152Completed105Est. Nov 2023
NCT05720494Completed24Est. Sep 2023
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
2 programs
2
BLU-808Phase 11 trial
ElenestinibPhase 1Small Molecule1 trial
Active Trials
NCT06948032Completed95Est. Jan 2025
NCT07388511Recruiting20Est. Apr 2026
Ipsen
IpsenChina - Tianjin
2 programs
2
Botulinum toxin type APhase 11 trial
elafibranorPhase 11 trial
Active Trials
NCT04970407Completed45Est. Jun 2022
NCT05564208Completed34Est. Jan 2023
Debiopharm
DebiopharmSwitzerland - Lausanne
2 programs
2
Debio 1450Phase 11 trial
Debio 1453PPhase 1
Active Trials
NCT03209648CompletedEst. Aug 2017
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
2
RO7062931Phase 11 trial
RO7795081Phase 11 trial
Active Trials
NCT03505190Completed41Est. Jul 2019
NCT06809608Completed36Est. Jun 2025
Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
2 programs
2
VonoprazanPhase 11 trial
VonoprazanPhase 11 trial
Active Trials
NCT04729101CompletedEst. Jun 2021
NCT04558216WithdrawnEst. Feb 2021
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
BGB-45035Phase 11 trial
Active Trials
NCT06342713RecruitingEst. May 2026
BioVersys
1 program
1
BV100Phase 11 trial
Active Trials
NCT05537142Completed33Est. Oct 2024
Insmed
InsmedBRIDGEWATER, NJ
1 program
1
Brensocatib Oral SolutionPhase 11 trial
Active Trials
NCT06344728Completed24Est. May 2024
Celldex Therapeutics
1
CDX-622Phase 11 trial
Active Trials
NCT06650761Active Not Recruiting85Est. Apr 2026
CSL Behring
1 program
1
CSL312Phase 11 trial
Active Trials
NCT05306275Completed132Est. Sep 2022
DT
1 program
1
DF5112Phase 11 trial
Active Trials
NCT07232121RecruitingEst. Dec 2026
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
EmraclidinePhase 13 trials
Active Trials
NCT05935033Completed38Est. Feb 2025
NCT05644977Completed17Est. Apr 2025
NCT05443724Completed700Est. Jun 2025

+8 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaBaxdrostat
AstraZenecaBaxdrostat
AstraZenecaBaxdrostat
AstraZenecaBaxdrostat
AstraZenecaTozorakimab
AstraZenecaTozorakimab
AstraZenecaTozorakimab
AstraZenecaTozorakimab
RegeneronREGN10933 + REGN10987
TevaTbo-filgrastim
AstraZenecaTozorakimab
AstraZenecaTozorakimab
AstraZenecaAZD5004
AstraZenecaAZD5004
AstraZenecaBaxdrostat

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 15,277 patients across 50 trials

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

Start: Aug 2025Est. completion: Feb 2028180 patients
Phase 3Recruiting

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Start: Apr 2024Est. completion: Apr 2026326 patients
Phase 3Active Not Recruiting

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

Start: Mar 2024Est. completion: Aug 2025218 patients
Phase 3Completed

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Start: Nov 2023Est. completion: Oct 2025796 patients
Phase 3Completed

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Start: Sep 2023Est. completion: May 20261,454 patients
Phase 3Active Not Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Start: Dec 2022Est. completion: Jun 20262,870 patients
Phase 3Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Start: Feb 2022Est. completion: Mar 20261,172 patients
Phase 3Active Not Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Start: Jan 2022Est. completion: Mar 20261,132 patients
Phase 3Active Not Recruiting
NCT04452318RegeneronREGN10933 + REGN10987

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Start: Jul 2020Est. completion: Oct 20213,303 patients
Phase 3Completed
NCT03029000TevaTbo-filgrastim

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

Start: Aug 2017Est. completion: Oct 20171 patients
Phase 3Terminated

A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

Start: Apr 2025Est. completion: Apr 202698 patients
Phase 2Active Not Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Start: Mar 2025Est. completion: Mar 2028540 patients
Phase 2Recruiting

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Start: Oct 2024Est. completion: Dec 2025406 patients
Phase 2Completed

Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

Start: Oct 2024Est. completion: Nov 2025310 patients
Phase 2Completed

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

Start: Jun 2024Est. completion: Dec 202448 patients
Phase 2Completed
NCT06116591PfizermPnC candidate

A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers

Start: Nov 2023Est. completion: May 2024105 patients
Phase 2Completed

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Start: Sep 2022Est. completion: Jun 2025700 patients
Phase 2Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

Start: Dec 2020Est. completion: Nov 2023137 patients
Phase 2Completed
NCT02190721TevaTbo-filgrastim

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

Start: May 2015Est. completion: Apr 201750 patients
Phase 2Completed

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

Start: Mar 2026Est. completion: Jul 202632 patients
Phase 1Not Yet Recruiting

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

Start: Mar 2026Est. completion: Jun 202664 patients
Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

Start: Feb 2026Est. completion: Jul 202686 patients
Phase 1Not Yet Recruiting

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Start: Feb 2026Est. completion: Apr 2026
Phase 1Active Not Recruiting

A Study of Elenestinib in Healthy Adult Female Participants

Start: Feb 2026Est. completion: Apr 202620 patients
Phase 1Recruiting

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults

Start: Jan 2026Est. completion: Dec 2026
Phase 1Recruiting

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

Start: Dec 2025Est. completion: Sep 2026
Phase 1Not Yet Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

Start: Dec 2025Est. completion: Dec 202696 patients
Phase 1Recruiting

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Start: Nov 2025Est. completion: Dec 202514 patients
Phase 1Completed
NCT07220954AstraZenecaAZD6234 Formulation 1

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Start: Nov 2025Est. completion: Mar 202621 patients
Phase 1Not Yet Recruiting

A Study to Assess the Effect of Food on the Drug Levels of Admilparant

Start: Nov 2025Est. completion: Jan 202656 patients
Phase 1Completed

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

Start: Sep 2025Est. completion: Mar 2026218 patients
Phase 1Active Not Recruiting
NCT06749236Vigonvitatest formulation

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension

Start: Aug 2025Est. completion: Sep 2025
Phase 1Completed

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

Start: Jul 2025Est. completion: Jul 202615 patients
Phase 1Recruiting

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Start: Jun 2025Est. completion: Sep 2025
Phase 1Completed

A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults

Start: Jun 2025Est. completion: May 202688 patients
Phase 1Recruiting
NCT07020988UCB PharmaStaccato Alprazolam

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

Start: Jun 2025Est. completion: Jan 202655 patients
Phase 1Completed

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Start: Jun 2025Est. completion: Dec 202675 patients
Phase 1Recruiting

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

Start: May 2025Est. completion: Jan 202651 patients
Phase 1Completed

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

Start: May 2025Est. completion: Jul 202516 patients
Phase 1Completed

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Start: May 2025Est. completion: Oct 202549 patients
Phase 1Completed

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Start: May 2025Est. completion: Oct 2025
Phase 1Completed

A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants

Start: Apr 2025Est. completion: Jun 202532 patients
Phase 1Completed

An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

Start: Apr 2025Est. completion: Nov 2025254 patients
Phase 1Completed

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Start: Mar 2025Est. completion: Feb 202636 patients
Phase 1Completed

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

Start: Mar 2025Est. completion: Nov 202544 patients
Phase 1Completed
NCT06911567TevaTEV-56286 Test

A Study to Assess New Formulations of TEV-56286

Start: Mar 2025Est. completion: Jun 202547 patients
Phase 1Completed

A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

Start: Mar 2025Est. completion: May 20258 patients
Phase 1Completed

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

Start: Feb 2025Est. completion: May 202518 patients
Phase 1Completed

Drug-Drug Interaction Potential of Mavorixafor

Start: Feb 2025Est. completion: May 2025
Phase 1Completed

A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

Start: Feb 2025Est. completion: Jun 202536 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
10 actively recruiting trials targeting 15,277 patients
30 companies competing in this space